NCT07031700 2025-06-22A Multicenter, Single-Arm, Open-Label, Phase II Trial of Mosunetuzumab in Combination With Tislelizumab for r/r FLTianjin Medical University Cancer Institute and HospitalPhase 2 Not yet recruiting22 enrolled